deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01163084

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients With Locally Advanced Adenocarcinoma of the Prostate

Sponsor: National Cancer Institute (NCI)

Conditions Prostate Adenocarcinoma Stage IIA Prostate Cancer AJCC v7 Stage IIB Prostate Cancer AJCC v7
Interventions Goserelin Acetate Laboratory Biomarker Analysis Leuprolide Acetate Vismodegib
Updated 14 times since 2017 Last updated: Feb 6, 2019 Started: Jul 9, 2010 Primary completion: Jun 1, 2012 Completion: Jun 1, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Prostate Adenocarcinoma trials with similar outcome

Browse all Prostate Adenocarcinoma trials

Listed as NCT01163084, this PHASE1/PHASE2 trial focuses on Prostate Adenocarcinoma and Stage IIA Prostate Cancer AJCC v7 and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 14 times since 2010, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Jan 2021 · 22 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE1_PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 9 earlier versions

  1. Mar 2019 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  2. Jun 2018 — Mar 2019 [monthly]

    Terminated PHASE1_PHASE2

  3. May 2018 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  4. Dec 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Nov 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Oct 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jun 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations